Arch Cardiol Mex. 2026 Jul 16. doi: 10.24875/ACM.25000084. Online ahead of print.
ABSTRACT
BACKGROUND: Thoracic aortic pathologies comprise a broad group of conditions affecting one or more layers of the aorta, some of which are known to be life-threatening. The development of thoracic aortic endovascular repair (TEVAR) has enabled a minimally invasive approach for treating these cases, with excellent long-term results.
OBJECTIVE: To describe clinical and technical outcomes of patients who underwent thoracic endovascular aortic repair (TEVAR) in a single tertiary care center.
METHOD: An observational, descriptive, retrospective cohort study. We included patients of 18 years-old or older who underwent TEVAR either as a single procedure or as part of a hybrid repair, between 2011 and 2023, in the Cardiology Hospital of the National Medical Centre XXI Century.
RESULTS: A total of 66 patients were included, of whom 77.2% were men. The most frequent cardiovascular risk factors were hypertension and tobacco use. TEVAR was performed as a single procedure in 57.6% (n = 38) and as a hybrid repair in 42.4% (n = 28). Technical success was achieved in 95.4% (n = 63). Event-free survival was 81.8% (n = 54) during hospitalization, 81.5% (n = 54) at 30 days, 76.9% (n = 50) at 1 year, 75.4% (n = 43) at 5 years, and 63.6% (n = 21) at 10 years. Adverse events occurred in 27.2% (n = 18) of cases, most commonly vascular access complications (12.1%, n = 8), spinal cord ischemia (4.5%, n = 3), and reintervention (4.5%, n = 3).
CONCLUSION: In this retrospective single-center experience, TEVAR demonstrated high technical success and acceptable mid- and long-term event-free survival. These findings support the feasibility and effectiveness of TEVAR in a tertiary-level care setting.
PMID:42463473 | DOI:10.24875/ACM.25000084